澳洋健康收盘下跌1.38%，滚动市盈率96.52倍，总市值27.34亿元

Company Overview - Aoyang Health's closing price on May 28 was 3.57 yuan, down 1.38%, with a rolling PE ratio of 96.52 times and a total market value of 2.734 billion yuan [1] - The company operates in the medical services, pharmaceutical distribution, and biotechnology sectors, with main products including medical services and pharmaceutical logistics [1] Financial Performance - In Q1 2025, Aoyang Health reported revenue of 452 million yuan, a year-on-year decrease of 22.27%, and a net profit of 18.4992 million yuan, down 39.82% [2] - The company's gross profit margin was 15.09% [2] Shareholder Information - As of March 31, 2025, Aoyang Health had 53,714 shareholders, a decrease of 3,624 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Industry Comparison - The average PE ratio for the medical services industry is 38.04 times, with a median of 42.05 times, placing Aoyang Health at 41st in the industry ranking [2] - The company’s PE ratio is significantly higher than the industry average, indicating potential overvaluation compared to peers [2] Achievements and Recognition - Aoyang Health's medical institutions have received various honors, including awards in national hospital quality improvement competitions and recognition as a top non-public hospital in China [1] - The company has signed an agreement with the China Trauma Rescue Alliance to enhance its trauma care capabilities [1]